Last reviewed · How we verify
Inactivated Influenza Vaccine
Inactivated Influenza Vaccine is a vaccine Biologic drug developed by St. Louis University. It is currently FDA-approved for Prevention of seasonal influenza in adults and children. Also known as: IIV, FLUARIX, VAXIGRIP®, Sanofi Pasteur, Fluzone.
The inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains without causing infection.
The inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains without causing infection. Used for Prevention of seasonal influenza in adults and children.
At a glance
| Generic name | Inactivated Influenza Vaccine |
|---|---|
| Also known as | IIV, FLUARIX, VAXIGRIP®, Sanofi Pasteur, Fluzone, Vaxigrip, Shenzhen Aventis Pasteur Biological |
| Sponsor | St. Louis University |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains chemically inactivated (killed) influenza virus particles or recombinant viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, B cells produce neutralizing antibodies against viral surface proteins (hemagglutinin and neuraminidase), while T cells develop memory to recognize infected cells, providing protection against subsequent natural infection with matching or similar viral strains.
Approved indications
- Prevention of seasonal influenza in adults and children
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (PHASE2)
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactivated Influenza Vaccine CI brief — competitive landscape report
- Inactivated Influenza Vaccine updates RSS · CI watch RSS
- St. Louis University portfolio CI
Frequently asked questions about Inactivated Influenza Vaccine
What is Inactivated Influenza Vaccine?
How does Inactivated Influenza Vaccine work?
What is Inactivated Influenza Vaccine used for?
Who makes Inactivated Influenza Vaccine?
Is Inactivated Influenza Vaccine also known as anything else?
What drug class is Inactivated Influenza Vaccine in?
What development phase is Inactivated Influenza Vaccine in?
What are the side effects of Inactivated Influenza Vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: St. Louis University — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of seasonal influenza in adults and children
- Also known as: IIV, FLUARIX, VAXIGRIP®, Sanofi Pasteur, Fluzone, Vaxigrip, Shenzhen Aventis Pasteur Biological
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing